ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BioMarin Pharmaceutical and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BioMarin PharmaceuticalSanofi
studies on the registry1722,425
open to participants now18105
phase 3 studies under way961
reach primary completion within a year564
programswith a study of their own in two years880+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBioMarin PharmaceuticalSanofi
Phase 1

BioMarin Pharmaceutical: 1 of its 8 programs at phase 1

  1. BMN 349phase 1
13%
28%
Phase 2

BioMarin Pharmaceutical: 1 of its 8 programs at phase 2

  1. BMN 351phase 2
13%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%
Phase 3

BioMarin Pharmaceutical: 4 of its 8 programs at phase 3

  1. vosoritidephase 3
  2. migalastatphase 3
  3. BMN 333phase 3
  4. efmirenpase alfaphase 3
50%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

BioMarin Pharmaceutical: 2 of its 8 programs at approved, new studies

  1. pegvaliaseapproved, new study
  2. RDD to Palynziqapproved, new study
25%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BioMarin Pharmaceutical3 readouts · 2 phase 3·

BioMarin Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. migalastatphase 3 · Dec 31 · NCT04020055
···

BioMarin Pharmaceutical, Apr ’27: 1 program whose next study reaches primary completion

  1. BMN 351phase 2 · Apr 14 · NCT06280209
····

BioMarin Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pegvaliaseapproved, new study · Sep 30 · NCT07477691
·
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BioMarin Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 4

  • vosoritidephase 2 · terminated Nov 13“BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibil…” · NCT06668805
  • efmirenpase alfaphase 2 · terminated Oct 19 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT06462547
  • efmirenpase alfaphase 1 · terminated Oct 15 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT05734196
  • efmirenpase alfaphase 3 · terminated Oct 1 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT06046820

Primary completion later 0

None

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionBioMarin PharmaceuticalSanofi
alpha 1-Antitrypsin Deficiencyboth · compare here

BioMarin Pharmaceutical in alpha 1-Antitrypsin Deficiency: 1 program

  1. BMN 349phase 1

Their studies: BioMarin Pharmaceutical’s studies of alpha 1-Antitrypsin Deficiency in search

Sanofi in alpha 1-Antitrypsin Deficiency: 2 programs

  1. efdoralprin alfaphase 2
  2. efdoralprin alfano phase

Their studies: Sanofi’s studies of alpha 1-Antitrypsin Deficiency in search

Fabry Diseaseboth · compare here

BioMarin Pharmaceutical in Fabry Disease: 1 program

  1. migalastatphase 3

Their studies: BioMarin Pharmaceutical’s studies of Fabry Disease in search

Sanofi in Fabry Disease: 1 program

  1. venglustatphase 3

Their studies: Sanofi’s studies of Fabry Disease in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: BioMarin Pharmaceutical 2 of 8 · Sanofi 53 of 80 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).